Filing Details

Accession Number:
0001170362-14-000005
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-04-24 18:14:48
Reporting Period:
2014-04-22
Filing Date:
2014-04-24
Accepted Time:
2014-04-24 18:14:48
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1080709 Arena Pharmaceuticals Inc ARNA Pharmaceutical Preparations (2834) 232908305
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1207600 Jr F Harry Hixson C/o Arena Pharmaceuticals, Inc.
6154 Nancy Ridge Drive
San Diego CA 92121
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-04-22 25,000 $4.11 107,876 No 4 M Direct
Common Stock Acquisiton 2014-04-22 11,900 $4.11 119,776 No 4 M Direct
Common Stock Disposition 2014-04-22 36,900 $6.31 82,876 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2014-04-22 25,000 $0.00 25,000 $4.11
Common Stock Stock Option (right to buy) Disposition 2014-04-22 11,900 $0.00 11,900 $4.11
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2004-09-14 2014-09-14 No 4 M Direct
2,699 2004-09-14 2014-09-14 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $6.25 and $6.335 per share, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The options were exercisable upon grant, but vested in two equal annual installments beginning on September 14, 2005.